Colistin Acinetobacter infection

Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/phar-macodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter bau-mannii meningitis. Eur J CUn Microbiol Infect Dis 2002 21(3) 212-14. 

Nervous system Of 7 patients from a Thai hospital and 17 patients who received intrathecal cohstin for drug-resistant Acinetobacter baumannii central nervous system infection identified in a literature review, three developed chemical ventriculitis and one had treatment-emergent seizures [101 ]. The dosage regimens of intrathecal colistin varied. There was an overall clinical cure rate of 83% and a microbiological cure rate of 92%. 

Khawcharoenporn T, Apisamthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection a case series and systematic review. Clin Microbiol Infect 2010 16(7) 888-94. 

A retrospective matched case-control study was carried out to determine the effect of inhaled colistin (160 mg twice daily) in patients with multidrug resistant Acinetobacter baumannii infection. The majority of patients reviewed were intensive care patients with baseline renal impairment. After 28 days of treatment, 17.9% developed haemodynamic instability, 30.6% developed acute renal failure and 20.8% required intubation. These results were not different to the control group and highlight the poor clinical state of the patient rather than the antibiotic used [137 ]. 

Kuo SC, Lee YT, Yang SP, Chen CP, Chen TL, Hsieh SL, et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate a matched case-control study. Clin Microbiol Infect 2012 18(9) 870-6. 

---